ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma

Karen M. Winkfield, Ranjana H. Advani, Leslie K. Ballas, Bouthaina S. Dabaja, Sughosh Dhakal, Christopher R. Flowers, Chul Soo Ha, Bradford S. Hoppe, David B. Mansur, Nancy P. Mendenhall, Monika L. Metzger, John P. Plastaras, Kenneth B. Roberts, Ronald Shapiro, Sonali M. Smith, Stephanie A. Terezakis, Anas Younes, Louis S. Constine

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

This topic addresses the management of recurrent Hodgkin lymphoma. While autologous stem cell transplantation may be appropriate for select cases of recurrent disease following comprehensive combined-modality therapy, other options exist for patients treated with lower-dose therapy for early-stage disease. Additionally, innovative targeted therapies provide newer salvage options to consider. The American College of Radiology Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation, or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

Original languageEnglish (US)
Pages (from-to)1099-103, 1106-8
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number12
StatePublished - Dec 15 2016

Fingerprint

Dive into the research topics of 'ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this